Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.4
USERS' SCORE
Good
Based on 29 Reviews
8
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin K₂ (as MK-7 [Menaquinone-7])
90 mcg
†
Top Medical Research Studies
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
Read More
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
Read More
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
Read More
Most Useful Reviews
7.5
Supports elasticity
55 people found this helpful
IMPORTANT!!! Take with high doses of vitamin D3, above 5000 IU! When consuming high D3 doses, take vitamin K2 as MK-7. K2 assists in blood clotting, cleanses blood vessels, and supports cardiovascular health by preventing calcium build-up.
Read More
9
Aids calcium use
26 people found this helpful
Taking vitamin D3 with K2 is essential for bone metabolism. K2, especially in MK-7 form, aids calcium distribution and prevents it from building up in the arteries, thus reducing cardiovascular disease risk.
Read More
9
Protects bone health
8 people found this helpful
This K2 MK-7 is fantastic! K2 does not induce blood clotting like K1. It plays a vital role in calcium distribution and helps prevent cardiovascular disease. High D3 doses require K2 for proper mineral metabolism.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.4
- All Researches
9
Impact of renal function on anticoagulation
We explored how kidney function impacts the safety and effectiveness of different anticoagulant therapies in patients with atrial fibrillation. By analyzing data from the GLORIA-AF registry involving over 10,000 patients, we found that better kidney function was linked to lower risks of serious health events.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Read More
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
Read More
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
Read More
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
Read More
7
Atrial fibrillation treatment effectiveness confirmed
We explored how closely real-world patients with atrial fibrillation matched the results from major trials using apixaban and rivaroxaban compared to vitamin K antagonists. By tracking patients from the GARFIELD-AF registry, we observed that these real-life outcomes on stroke prevention, bleeding, and mortality closely mirrored those of the original trials. The study found that while the real-world patients had lower cardiovascular risks, the efficacy and safety of the treatments remained strong and comparable. This demonstrates that the findings from the ARISTOTLE and ROCKET AF trials are relevant in everyday clinical settings.
Read More
User Reviews
USERS' SCORE
Good
Based on 29 Reviews
8
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Supports elasticity
55 people found this helpful
IMPORTANT!!! Take with high doses of vitamin D3, above 5000 IU! When consuming high D3 doses, take vitamin K2 as MK-7. K2 assists in blood clotting, cleanses blood vessels, and supports cardiovascular health by preventing calcium build-up.
Read More
9
Aids calcium use
26 people found this helpful
Taking vitamin D3 with K2 is essential for bone metabolism. K2, especially in MK-7 form, aids calcium distribution and prevents it from building up in the arteries, thus reducing cardiovascular disease risk.
Read More
9
Protects bone health
8 people found this helpful
This K2 MK-7 is fantastic! K2 does not induce blood clotting like K1. It plays a vital role in calcium distribution and helps prevent cardiovascular disease. High D3 doses require K2 for proper mineral metabolism.
Read More
9
Supports statin users
4 people found this helpful
Vitamin K supports calcium absorption, especially vital for those on statins. I recommend taking K2 (MK-7) to reduce cardiovascular disease risk and calcification of arteries while on medication.
Read More
9
Redirects calcium effectively
4 people found this helpful
K2 MK7 facilitates normal calcium absorption, bolstering bone strength and supporting cardiovascular health. With high D3 doses over 5000 IU, taking MK7 is crucial. It regulates calcium levels essential for bone and cardiovascular health and may even possess anti-cancer properties.
Read More
Frequently Asked Questions
10
Lifesaving supplement
2 people found this helpful
Vitamin K2 has been a lifesaver for me, helping to remove calcium plaque from my arteries and direct calcium back into my bones, thus reducing my risk of cardiovascular disease. It's an underappreciated vitamin that may one day be as recognised and essential as Vitamin C.
9
Supports cardiovascular health
Excellent! It’s important to take high doses of vitamin D3 above 5000 IU along with K2 in the MK-7 form as a preventive measure. K2 is a cofactor for D3, improving vascular elasticity and blood clotting, and it may help combat cardiovascular disease, diabetes, and osteoporosis.
7.5
Supports elasticity
55 people found this helpful
IMPORTANT!!! Take with high doses of vitamin D3, above 5000 IU! When consuming high D3 doses, take vitamin K2 as MK-7. K2 assists in blood clotting, cleanses blood vessels, and supports cardiovascular health by preventing calcium build-up.
9
Redirects calcium effectively
4 people found this helpful
K2 MK7 facilitates normal calcium absorption, bolstering bone strength and supporting cardiovascular health. With high D3 doses over 5000 IU, taking MK7 is crucial. It regulates calcium levels essential for bone and cardiovascular health and may even possess anti-cancer properties.
7.5
Reduces disease risk
5 people found this helpful
Vitamin K-2 MK7 is effective for blood clotting and for cleansing arteries. It improves calcium absorption and aids in treating cardiovascular disease, diabetes, and osteoporosis. I’m pleased I started using it.
7.5
Supports autoimmune diseases
1 people found this helpful
Taking Vitamin D with K2 has improved my bone health and helped my autoimmune diseases, including psoriasis.
9
Essential vitamins
1 people found this helpful
Gold Vitamin K2 in MK-7 form has high bioavailability and is crucial for calcium absorption and the prevention of osteoporosis and heart disease. I've significantly raised my Vitamin D3 levels and noticed improved mood and energy. I highly recommend it.
7.5
Prevents atherosclerosis
4 people found this helpful
Both vitamins D3 and K2 work together in bone metabolism. K2 MK-7 is essential for D3’s absorption, preventing calcium from depositing in soft tissues and arteries, thus aiding in the management of cardiovascular disease and arterial stiffness.
9
Aids calcium use
26 people found this helpful
Taking vitamin D3 with K2 is essential for bone metabolism. K2, especially in MK-7 form, aids calcium distribution and prevents it from building up in the arteries, thus reducing cardiovascular disease risk.
7.5
Prevents osteoporosis
1 people found this helpful
The MK-7, at a dose of 90 micrograms, is excellent for the prevention of osteoporosis. Jarrow Formulas® MK-7 is fermented from natto and is absorbed better than K1 from spinach. Compared to K1 and MK-4, MK-7 effectively aids in carboxylation of proteins crucial for bone and cardiovascular health.
7.5
Approved dosage
1 people found this helpful
As someone with osteopenia, I must take this. It's essential for those with vascular disease. While up to 300 is recommended daily, I find 90 suffices. This reliable ingredient comes from a trustworthy company.
9
Supports cardiovascular health
The Jarrow Formulas® MK-7 is a naturally fermented dietary supplement that is far better absorbed than K1 from spinach. This longer-acting vitamin K supports the carboxylation of proteins essential for healthy bones and helps address cardiovascular disease.
7.5
Promotes calcium exchange
14 people found this helpful
K2 MK-7 is the best bioavailable form. It’s sensible to take K along with D, as both vitamins positively impact bone health and cardiovascular disease by supporting calcium management in the body.
6
Vital for health
1 people found this helpful
Vitamin K2, especially MK-7, is crucial for calcium metabolism, guiding it to bone tissue and preventing its accumulation in arteries, thus helping to manage cardiovascular disease.
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
9
Impact of renal function on anticoagulation
We explored how kidney function impacts the safety and effectiveness of different anticoagulant therapies in patients with atrial fibrillation. By analyzing data from the GLORIA-AF registry involving over 10,000 patients, we found that better kidney function was linked to lower risks of serious health events.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
References
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. doi:10.1007/s11739-025-03922-6
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. doi:10.36660/abc.20240147
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. doi:10.1007/s11239-025-03067-5
- Schipper JH, Sommer AS, Nies RJ, Metze C, Meertens MM, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Atrial Fibrillation: A Single-Center Observational Study. J Am Heart Assoc. 2025;14:e038834. doi:10.1161/JAHA.124.038834
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. doi:10.1136/openhrt-2024-002966
